Product Wiki · Recalls · Health Canada Consumer Product Safety

Recall 22844 — Archived - Desmopressin nasal sprays (including Apo-Desmopressin Spray) are associated with an increased risk of serious side effects involving water retention and decreased blood sodium levels (hyponatremia). - For the Public

Health Canada Consumer Product Safety · Canada · 2008-08-06

AI-assisted, human-edited — this page is drafted with AI from public-source data, then reviewed before publication. How we use AI →
Agency
Health Canada Consumer Product Safety
Recall identifier
22844
Date of alert
2008-08-06
Country / jurisdiction
Canada
Risk type
recall
Product category
Drugs
Product type
Marketed health products
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/archived-desmopressin-nasal-sp

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

Related

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.